Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system

References

• Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• D'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:320–328.
   PubMed Web of Science ®Google Scholar
• McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3–10.
   PubMed Web of Science ®Google Scholar
• Kaul M, Stuart A. Lipton: mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol. 2006;1:138–151.
   PubMed Web of Science ®Google Scholar
• González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69–81.
   PubMed Web of Science ®Google Scholar
• Shacklett BL, Cox CA, Wilkens DT, Karl Karlsson R, Nilsson A, Nixon DF, et al. Increased adhesion molecule and chemokine receptor expression on CD8+T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis. 2004;189(12):2202–2212.
   PubMed Web of Science ®Google Scholar
• Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol. 2007;2:112–119.
   PubMed Web of Science ®Google Scholar
• Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008;47(5):544–552.
   PubMed Web of Science ®Google Scholar
• Ho EL, Ronquillo R, Altmeppen H, Spudich SS, Price RW, Sinclair E. Cellular composition of cerebrospinal fluid in HIV-1 infected and uninfected subjects. PLoS One. 2013;8(6):e66188.
   PubMed Web of Science ®Google Scholar
• Maxeiner HG, Rojewski MT, Schmitt A, Tumani H, Bechter K, Schmitt M. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Brain Behav Immun. 2009;23(1):134–134.
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Grummel V, Wemlinger S, Buck D, Weber MS, Berthele A, et al. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. J Neurol. 2014;261(1):130–143.
   PubMed Web of Science ®Google Scholar
• Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, et al. Multicenter AIDS cohort study: predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29(4):346–355.
   PubMed Web of Science ®Google Scholar
• Vigano A, Saresella M, Villa ML, Ferrante P, Clerici M. CD38+CD8+T cells as a marker of poor response to therapy in HIV-infected individuals. Chem Immunol. 2000;75:207–217.
   PubMed Web of Science ®Google Scholar
• Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7(1):4–10.
   PubMedGoogle Scholar
• Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC. Determinants of CD4+T cell recovery during suppressive antiretroviral therapy: association of immune activation. T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006;194:29–37.
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
   PubMed Web of Science ®Google Scholar
• Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D. Mechanisms of HIV-1 neurotropism. Curr HIV Res. 2006;4(3):267–278.
   PubMed Web of Science ®Google Scholar
• Olivares I, Sánchez-Jiménez C, Vieira CR, Toledano V, Gutiérrez-Rivas M, López-Galíndez C. Evidence of ongoing replication in a human immunodeficiency virus type 1 persistently infected cell line. J Gen Virol. 2013;94(Pt 5):944–954.
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013;207(11):1703–1712.
   PubMed Web of Science ®Google Scholar
• Xiao J, Gao G, Li Y, Zhang W, Tian Y, Huang Y, et al. Spectrums of opportunistic infections and malignancies in HIV-infected patients in tertiary care hospital, China. Plos One. 2013;8(10):e75915.
   PubMed Web of Science ®Google Scholar
• Mullen KM, Gocke AR, Allie R, Ntranos A, Grishkan P IV, ardo C, et al. Expression of CCR7 and CD45RA in CD4+ and CD8+ subsets in cerebrospinal fluid of 134 patients with inflammatory and non-inflammatory neurological diseases. J Neuroimmunol. 2012;249(1-2):86–92.
   PubMed Web of Science ®Google Scholar
• Dotta L, Badolato R. Primary immunodeficiencies appearing as combined lymphopenia, neutropenia, and monocytopenia. Immunol Lett. 2014;161(2):222–225.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Hatano H, Sinclair E, Lee TH, Busch MP, Martin JN, et al. HIV-specific CD4+T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis. 2011;52(5):681–687.
   PubMed Web of Science ®Google Scholar
• Lok JJ, Hunt PW, Collier AC, Benson CA, Witt MD, Luque AE, et al. The impact of age on the prognostic capacity of CD8+T-cell activation during suppressive antiretroviral therapy. AIDS. 2013;27(13):2101–2110.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, et al. CD8+T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr. 2013;63(1):101–104.
   PubMed Web of Science ®Google Scholar
• Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425–1431.
   PubMed Web of Science ®Google Scholar
• Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, Giorgi JV, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12(13):1581–1590.
   PubMed Web of Science ®Google Scholar
• Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83–92.
   PubMedGoogle Scholar
• Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+T-cell changes independent of viral load. Blood. 2004;104(4):942–947.
   PubMed Web of Science ®Google Scholar
• Conrad JA, Ramalingam RK, Duncan CB, Smith RM, Wei J, Barnett L, et al. Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance. J Virol. 2012;86(8):4213–4221.
   PubMed Web of Science ®Google Scholar
• Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9(2):139–147.
   PubMed Web of Science ®Google Scholar
• Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Neurocognitive Disord HIV. 2011;19(4):137–142.
   Google Scholar